Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition.

[1]  A. Krüger.  Functional genetic mouse models: promising tools for investigation of the proteolytic internet , 2009, Biological chemistry.

[2]  A. Krüger,et al.  Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. , 2008, Human gene therapy.

[3]  B. Fingleton,et al.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. , 2008, Cancer research.

[4]  David R. Croucher,et al.  Revisiting the biological roles of PAI2 (SERPINB2) in cancer , 2008, Nature Reviews Cancer.

[5]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[6]  X. Puente,et al.  Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. , 2008, Cancer research.

[7]  A. Krüger,et al.  Distinct Functionality of Tumor Cell–Derived Gelatinases during Formation of Liver Metastases , 2008, Molecular Cancer Research.

[8]  A. Noël,et al.  Matrix metalloproteinases at cancer tumor-host interface. , 2008, Seminars in cell & developmental biology.

[9]  L. Trusolino,et al.  The Met tyrosine kinase receptor in development and cancer , 2008, Cancer and Metastasis Reviews.

[10]  C. Overall,et al.  Protease research in the era of systems biology , 2007, Biological chemistry.

[11]  A. Krüger,et al.  Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. , 2007, Cancer research.

[12]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[13]  H. Kwaan,et al.  The Plasminogen Activator System and Cancer , 2007, Pathophysiology of Haemostasis and Thrombosis.

[14]  M. Hendrix,et al.  Influence of the microenvironment on melanoma cell fate determination and phenotype. , 2006, Cancer research.

[15]  V. Laurent-Matha,et al.  Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. , 2006, Cancer letters.

[16]  O. Vasiljeva,et al.  Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. , 2006, Cancer research.

[17]  H. Nielsen,et al.  Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[18]  Xu-wen Liu,et al.  Novel functions of TIMPs in cell signaling , 2006, Cancer and Metastasis Reviews.

[19]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[20]  S. Mobashery,et al.  Recent advances in MMP inhibitor design , 2006, Cancer and Metastasis Reviews.

[21]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[22]  S. Meroueh,et al.  Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. , 2005, Organic letters.

[23]  A. Krüger,et al.  Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. , 2005, Cancer research.

[24]  P Cuniasse,et al.  Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. , 2005, Biochimie.

[25]  D. Hanahan,et al.  Multiple Roles for Cysteine Cathepsins in Cancer , 2004, Cell cycle.

[26]  Achim Krüger,et al.  Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents*[boxs] , 2004, Journal of Biological Chemistry.

[27]  Nasreen S Jessani,et al.  Activity-based probes for the proteomic profiling of metalloproteases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. López-Otín,et al.  Loss of collagenase-2 confers increased skin tumor susceptibility to male mice , 2003, Nature Genetics.

[29]  Maria Pavlaki,et al.  Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials , 2003, Cancer and Metastasis Reviews.

[30]  W. Bode,et al.  Structural Basis of the Matrix Metalloproteinases and Their Physiological Inhibitors, the Tissue Inhibitors of Metalloproteinases , 2003, Biological chemistry.

[31]  A. Krüger,et al.  Increase of Anti-Metastatic Efficacy by Selectivity- But Not Affinity-Optimization of Synthetic Serine Protease Inhibitors , 2003, Biological chemistry.

[32]  A. Krüger,et al.  Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. , 2002, Cancer research.

[33]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[34]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[35]  A. Harris,et al.  Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Krüger,et al.  Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. , 2001, Cancer research.

[37]  H. Krell,et al.  Pyrimidine-2,4,6-Triones: A New Effective and Selective Class of Matrix Metalloproteinase Inhibitors , 2001, Biological chemistry.

[38]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[39]  J. Foidart,et al.  Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. , 2000, Experimental cell research.

[40]  P. Slocombe,et al.  The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 , 2000, FEBS letters.

[41]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[42]  A. Krüger,et al.  Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. , 1999, Anticancer research.

[43]  M. Schmitt,et al.  Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). , 1998, International journal of oncology.

[44]  P. Comoglio,et al.  Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. , 1997, Cytokine & growth factor reviews.

[45]  S. Shapiro,et al.  Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[46]  B. Hogan,et al.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  V. Dive,et al.  Third-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors , 2008 .

[48]  A. Krüger,et al.  Janus-Faced Effects of Broad-Spectrum and Specific MMP Inhibition on Metastasis , 2008 .

[49]  B. Fingleton.  MMP Inhibitor Clinical Trials – The Past, Present, and Future , 2008 .

[50]  D. Edwards.  The cancer degradome : proteases and cancer biology , 2008 .

[51]  Heath B Acuff,et al.  Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. , 2006, Cancer research.

[52]  H. Tsuzuki,et al.  Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor , 2004, Clinical & Experimental Metastasis.

[53]  Y. DeClerck,et al.  Proteases and protease inhibitors in tumor progression. , 1997, Advances in experimental medicine and biology.